These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Cyberknife and prostate cancer. In regard to King et al. (Int J Radiat Oncol Biol Phys 2009;73:1043-1048). Vikram B Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):632. PubMed ID: 19735890 [No Abstract] [Full Text] [Related]
9. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Suman VJ; Dueck A; Sargent DJ Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764 [No Abstract] [Full Text] [Related]
10. Examining heterogeneity in phase II trial designs may improve success in phase III. Tuma RS J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788 [No Abstract] [Full Text] [Related]
11. Optimizing randomized phase II trials assessing tumor progression. Stone A; Wheeler C; Carroll K; Barge A Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129 [TBL] [Abstract][Full Text] [Related]
12. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. El-Maraghi RH; Eisenhauer EA J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606 [TBL] [Abstract][Full Text] [Related]
13. Predicting success in phase III studies from phase II results: a new paradigm is needed. Leff R; Andrews M J Clin Oncol; 2008 Jul; 26(21):3653-4; author reply 3654-5. PubMed ID: 18640948 [No Abstract] [Full Text] [Related]
14. Improving the design of phase II trials of cytostatic anticancer agents. Stone A; Wheeler C; Barge A Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736 [TBL] [Abstract][Full Text] [Related]
15. The ethical and scientific case for phase 2C clinical trials. Zee YK; Chan SW; Harris J; Jayson GC Lancet Oncol; 2010 May; 11(5):410-1. PubMed ID: 20434710 [No Abstract] [Full Text] [Related]
16. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate]. Chen SS Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242 [No Abstract] [Full Text] [Related]
17. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers. Mills DA; Fekrazad HM; Verschraegen CF Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764 [TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors and new drugs in acute non-lymphoblastic leukemia]. Levy A; Pinkhas J Harefuah; 1983 Oct; 105(8):236-8. PubMed ID: 6681391 [No Abstract] [Full Text] [Related]